Novo Nordisk to bring fraud claim over hypertension drug
(Credit: Shutterstock/Kittyfly)
Danish pharmaceutical group Novo Nordisk is preparing to launch an ICC arbitration worth US$830 million against a Singapore biosciences company for alleged fraud, after acquiring a hypertension drug that failed in clinical trials.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now